Ó¢¹ú365¼¯ÍŹÙÍø

Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼Ó뿵ϣŵÉúÎï¸æ¿¢Õ½ÂÔºÏ×÷ ¹²Ì½mRNAÒßÃçÖ×ÁöÃâÒßмƻ®

2025-04-10

×ÖºÅ

       ¿ËÈÕ £¬Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼È«×Ê×Ó¹«Ë¾Ìì½òÓ¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼¡±£©Ó뿵ϣŵÉúÎï×Ó¹«Ë¾¿µÏ£ÅµÉúÎÉϺ££©ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°¿µÏ£ÅµÉúÎ£©Ç©ÊðºÏ×÷¿ª·¢Ð­Òé £¬Ë«·½½«ÅäºÏÍƽømRNAÒßÃçÓÃÓÚÖÎÁƽºÖÊĸϸ°ûÁö£¨GBM£©µÄÁÙ´²Ñо¿ÏîÄ¿ £¬Ô¤¼Æ½ñÄêÄÚÍê³ÉÊ×Àý»¼Õ߸øÒ© ¡£

       Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼ºÍ¿µÏ£ÅµÉúÎïͬΪÌì½òºËËṤҵͬÃ˵ijÉÔ±µ¥Î» £¬´ËÇ°Ë«·½ÔÚÒªº¦ÖÊÁÏÑз¢¼°½¹µãÊÖÒÕ֪ʶ²úȨ½á¹¹µÈÁìÓòÒѽ¨ÉèÓÅÒìºÏ×÷»ù´¡ ¡£±¾´ÎºÏ×÷½«³ä·ÖÑéÕ¹Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼ÔÚ¿¹Ö×ÁöÒ©Î￪·¢µÄ¸»ºñÂÄÀúÓ뿵ϣŵÉúÎïmRNAÊÖÒÕƽ̨µÄÐÛºñʵÁ¦ £¬Í¬Ê±Ò²ÎªË«·½ÔÚmRNAÒßÃçÖÎÁÆÖ×ÁöÁìÓòÉîÈë½»Á÷ºÍ½øÒ»²½ºÏ×÷µÓÚ¨»ù´¡ ¡£

       Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼ÖÕÄêרעÓÚÒ©ÎïµÝËÍÁìÓò £¬ÔÚÖ×ÁöÃâÒß·½ÃæºÍmRNAµÝË͵ÈÆ«Ïò¾ùÓнṹ ¡£Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼×ÔÖ÷Ñз¢µÄ¾ÛÒÒ¶þ´¼ÒÁÁ¢Ì濵(JK1201I)ÖÎÁÆÒ»ÏßÏ£ÍûÆÕ±éÆÚСϸ°û·Î°©ÕýÔÚ¾ÙÐÐÁÙ´²ÈýÆÚÑо¿ £¬ÄÔ½ºÖÊÁö˳Ӧ֢Óë°éÄÔתÒƵÄÈýÒõÐÔÈéÏÙ°©Ë³Ó¦Ö¢ÕýÔÚ¾ÙÐÐÁÙ´²¶þÆÚÑо¿ ¡£

       ¿µÏ£ÅµÉúÎｨÉèµÄmRNAÊÖÒÕƽ̨ £¬ÓµÓÐ×ÔÖ÷Éè¼Æ¡¢¿ª·¢µÄÐòÁÐÓÅ»¯Èí¼þ £¬¿É»ñµÃÓ°ÏìÎȹÌÐÔµÄÒªº¦Î»µã¼°ÓÐÓÃÌá¸ß¿¹Ô­±í´ïÁ¿µÄ×îÓÅÐòÁÐ £¬CMC¹¤ÒÕ¾«Á· £¬¿ÉÒÔËõ¶Ì²úÆ·¿ª·¢Ê±¼ä £¬¿ìËÙʵÏÖ¿ÆÑÐЧ¹û¹¤Òµ»¯ ¡£

       Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼½«ÒÀÍÐmRNAµÈÏȽøÊÖÒÕƽ̨ £¬³Ð¼ÌÒÔÖÊÁÏÁ¢ÒìÒýÁìÉúÎïÒ½Ò©Á¢ÒìµÄʹÃü £¬Ò»Á¬Í¨¹ýÐÂÐÍÒ©ÎïµÝËÍÊÖÒÕΪÖ×ÁöÃâÒß¡¢»ùÒòÖÎÁƵÈÁìÓò´øÀ´¸ü¶àÓÐÖúÓÚÈ«·½Î»ÌáÉý»¼Õ߸£ÀûµÄ½â¾ö¼Æ»® £¬Ð¯ÊÖЭ×÷»ï°éÅäºÏÔö½ø¡°ÈËÈËÏíÓÐÎÀÉú¿µ½¡¡±Ä¿µÄµÄʵÏÖ ¡£

 

¹ØÓÚ½ºÖÊĸϸ°ûÁö

½ºÖÊĸϸ°ûÁö£¨Ò²³ÆΪ¢ô¼¶ÐÇÐÎϸ°ûÁö£©ÊÇÌìÏÂÎÀÉú×éÖ¯È϶¨µÄIV¼¶½ºÖÊÁö £¬Ò²ÊÇ×î³£¼ûµÄ¶ñÐÔÔ­·¢ÐÔÄÔÖ×Áö £¬5ÄêÉúÑÄÂÊΪ7.2% ¡£¸ÃÖ×ÁöÉú³¤Ñ¸ËÙ £¬¶ñÐÔ¶È¸ß £¬Ö÷ҪλÓÚ´óÄÔ°ëÇò £¬Ò²¿É±¬·¢ÔÚÄԸɡ¢Ð¡ÄÔ°ëÇò»ò¼¹ËèµÈ £¬Ö÷Òª·¢²¡ÄêËêΪ45-60Ëê £¬ÄÐÐÔ½ÏÅ®ÐÔ·¢²¡ÂÊÂÔ¸ß £¬¶ùͯҲ¿ÉÒÔ·¢²¡ £¬ÇÒ¶à¼ûÓÚÄÔ¸É ¡£GBMµÄ¸ß¶È½þÈóÐÔ¡¢ÒÅ´«ÒìÖÊÐÔºÍѪÄÔÆÁÕϵı£»¤¸øÖÎÁÆ´øÀ´ÁËÖØ´óµÄÌôÕ½ ¡£ÏÖÔÚGBMµÄ±ê×¼ÖÎÁÆÊÇÊÖÊõÇгýºó¾ÙÐзŻ¯ÁÆ ¡£ÊÖÊõÇгýÖ×Áöºó¸´·¢½Ï¿ì £¬ÆäÔ¤ºóÊÇÄÔ½ºÖÊÁöÖнϲîµÄÒ»ÖÖ ¡£¡¾1¡¿

½üÄêÀ´ÃâÒßÁÆ·¨³ÉΪÐí¶àÖ×ÁöµÄÖ÷ÒªÖÎÁÆ·½·¨ £¬¿ÉÊÇÔÚÄÔ°©£¨°üÀ¨GBM£©µÄÖÎÁÆÉÐδȡµÃÍ»ÆÆ ¡£È¥ÄêÍâÑó¼¸ÏîʹÓÃmRNAÒßÃçµÄСÐÍÁÙ´²ÊÔÑéµÄЧ¹ûËƺõŤתÁËÕâÒ»Ç÷ÊÆ £¬Ïà¹ØµÄÑо¿±¨µÀÔÚNIHÉÏÓÐËù±¨µÀ[2] ¡£Í¬Äêһƪ½ÒÏþÔÚJ NanobiotechnologyµÄ×ÛÊö»ã×ÜÁËmRNAÒßÃçÔÚGBMµÄÓ¦Óá¾3¡¿ £¬Õ¹Ê¾ÁËÖ÷ÒªµÄÖÎÁÆDZÁ¦ ¡£

 

¹ØÓÚÓ¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼

Ó¢¹ú365¼¯ÍŹÙÍø£¨Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼688356.SH£©½¨ÉèÓÚ2001Äê £¬ÊÇÈ«ÇòÒ½ÓÃÒ©ÓþÛÒÒ¶þ´¼ÖÊÁÏÁìÓòµÄÖ÷ÒªÐÂÐ˼ÓÈëÕß £¬Îª¶à¿îÉÏÊÐPEG»¯Á¢ÒìÒ©Îï¼°Ò½ÁÆÆ÷е²úÆ·¹©Ó¦PEGÑÜÉúÎï ¡£Í¬Ê±¿ª·¢Á˺£ÄÚµÚÒ»¿îPEGżÁªÐ¡·Ö×ÓÒ©Îï £¬ÏÖÔÚ¸ÃÏîÄ¿´¦ÓÚÈýÆÚÁÙ´²½×¶Î ¡£Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼¾Û½¹mRNAµÝËÍϵͳ½¹µãÊÖÒÕ¹¥¹Ø £¬ÔÚÒªº¦Ö¬ÖÊÖÊÁÏÁìÓòÈ¡µÃÖ÷ҪͻÆÆ£ºÍ¨¹ý¶ÔÏÖÓеÝËÍϵͳÖÐÒªº¦Ö¬ÖÊÒòËؾÙÐÐÉú²ú¹¤ÒÕÓÅ»¯ £¬ÊµÏÖÁË5ÖÖÒªº¦¸¨ÁϵĹæÄ£»¯×ÔÖ÷ÖƱ¸ £¬Ïà¹ØÊÖÒÕ×ÊÁÏÒÑͨ¹ý¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ºÍÃÀ¹úFDAµÄÖÊÁÏÒ©Ö÷Îļþ£¨DMF£©Ë«Öر¸°¸£»Í¬²½¹¹½¨ÁË°üÀ¨ÊýÊ®ÖÖÁ¢Òì½á¹¹µÄÖ¬ÖÊ»¯ºÏÎï¿â £¬ÐγɾßÓÐ×ÔÖ÷֪ʶ²úȨµÄÊÖÒÕ¾ØÕó ¡£

 

¹ØÓÚ¿µÏ£ÅµÉúÎï

¿µÏ£ÅµÉúÎï¹É·Ý¹«Ë¾£¨¿µÏ£ÅµÉúÎï 06185.HK£»¿µÏ£Åµ 688185.SH£© £¬2009Ä꽨ÉèÓÚÖйú £¬ÖÂÁ¦ÓÚÔÚÌìϹæÄ£ÄÚÌṩԤ·ÀºÍÖÎÁÆѬȾÀ༲²¡µÄ½â¾ö¼Æ»® ¡£¹«Ë¾ÏÖÓв¡¶¾ÔØÌåÒßÃçÊÖÒÕ¡¢ºÏ³ÉÒßÃçÊÖÒÕ¡¢ÂѰ׽ṹÉè¼ÆºÍVLP×é×°ÊÖÒÕ¡¢mRNAÊÖÒÕ¡¢ÖƼÁ¼°¸øÒ©ÊÖÒÕÎå´óÁ¢ÒìÒßÃçƽ̨ÊÖÒÕ ¡£ÏÖÔÚÒѽ¨ÉèÁýÕÖ10ÓàÖÖ˳Ӧ֢µÄ¶à¿îÁ¢ÒìÒßÃç²úÆ· £¬°üÀ¨ÑÇÖÞÊ׿îËļÛÁ÷ÄÔÍŽáÒßÃçÂüº£ÐÀ?¡¢¶þ¼ÛÁ÷ÄÔÍŽáÒßÃçÃÀÄÎϲ?¡¢»ñµÃÊÀÎÀ×éÖ¯ÈϿɵÄйÚÒßÃç¿ËÍþɯ?¡¢È«ÇòÊ׿îÎüÈëÓÃйÚÒßÃç¿ËÍþɯ?ÎíÓÅ?ÒÔ¼°ÑÇÖÞÊ׸öÖØ×é°£²©À­²¡¶¾²¡ÒßÃç ¡£

 

Reference

[1] Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021 Sep;171:105780. doi: 10.1016/j.phrs.2021.105780. Epub 2021 Jul 21. PMID: 34302977; PMCID: PMC8384724.

[2] mRNA Vaccine Boosts Immune Response Against Glioblastoma - NCI

[3] Karimi-Sani I, Molavi Z, Naderi S, Mirmajidi SH, Zare I, Naeimzadeh Y, Mansouri A, Tajbakhsh A, Savardashtaki A, Sahebkar A. Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials. J Nanobiotechnology. 2024 Oct 4;22(1):601. doi: 10.1186/s12951-024-02882-x. PMID: 39367418; PMCID: PMC11453023.

Òªº¦´Ê£º

ÉÏÒ»Ò³

ϲ±¨ | Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

ÏÂÒ»Ò³

ÉÏÒ»Ò³£º

ϲ±¨ | Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

ÏÂÒ»Ò³£º

Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

ÍƼöÐÂÎÅ

¡¾Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼×¨Ìâ·ÖÏí¡¿ÓëÄúÏàÔ¼6ÔÂCPHIÖÆÒ©ÖÊÁÏÖÇÔ칤ҵÂÛ̳

2025-06-09

ϲ±¨ | Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

2025-04-27

Ó¢¹ú365¼¯ÍŹÙÍø¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

2025-03-06

·ÖÏíµ½

ÍøÕ¾µØͼ